Bio-Rad Laboratories (BIO.B) vs Glaukos (GKOS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Glaukos (GKOS) has outperformed Bio-Rad Laboratories (BIO.B) over the past year, gaining 84.1% versus a gain of 28.2%. Over five years, GKOS leads with a +259.9% price change compared with -50.5% for BIO.B. Bio-Rad Laboratories is the larger company by market cap ($9.76 billion vs $9.66 billion), about 1.0 times the size, while Glaukos is growing revenue faster (+32.3% vs +0.7%).
Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | GKOS |
|---|---|---|
| Share price | $365.08 | $163.72 |
| Market cap | $9.76B | $9.66B |
| 1-day change | 0.00% | +1.50% |
| YTD return | +17.50% | +42.85% |
| 1-year return | +28.15% | +84.14% |
| 5-year return | -50.54% | +259.86% |
| P/E ratio (TTM) | 46.27 | — |
| Forward P/E | — | 312.24 |
| EPS (TTM) | $7.89 | $-3.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $507.44M |
| Revenue growth (YoY) | +0.65% | +32.33% |
| Net income (latest FY) | $759.90M | $-187.69M |
| Gross margin | 51.87% | 55.72% |
| Operating margin | 1.83% | -39.33% |
| Net margin | 29.42% | -36.99% |
| 52-week high | $365.08 | $191.62 |
| 52-week low | $244.54 | $73.16 |
| Distance from 52-week high | 0.00% | -14.56% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +21.36% |
| Average volume | 6 | 831.71K |
| Shares outstanding | 5.06M | 58.98M |
| Employees | 7,450 | 1,094 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GKOS has outperformed BIO.B by 56.0 percentage points over the past year.
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
- Glaukos grew revenue faster in its latest fiscal year (+32.33% vs +0.65%).
- The two companies sit in different sectors: Bio-Rad Laboratories in Healthcare and Glaukos in Health Care.
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
BIO.B vs GKOS FAQ
Which is bigger, Bio-Rad Laboratories or Glaukos?
Bio-Rad Laboratories (BIO.B) is larger, with a market capitalization of $9.76B compared with $9.66B for Glaukos (GKOS).
Which stock has performed better over the past year, BIO.B or GKOS?
GKOS returned +84.14% over the past 12 months, compared with +28.15% for BIO.B (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and Glaukos in the same industry?
No. Bio-Rad Laboratories is in the Healthcare sector, while Glaukos is in Health Care.